What question did this study set out to answer?

To evaluate and compare the diagnostic performance of two commercial platforms (cobas SARS-CoV-2 and Amplidiag COVID-19) and a laboratory-developed test for detecting SARS-CoV-2 RNA in respiratory samples.

January 21, 2021Työväentutkimus VuosikirjaOpen Access

Comparison of Two Commercial Platforms and a Laboratory-Developed Test for Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA

View Full Paper

Ask AI

Bookmark

Authors

LMLaura MannonenUniversity of Helsinki HKHannimari Kallio‐KokkoUniversity of Helsinki RLRaisa LoginovUniversity of Helsinki

Discussion

Member takes

Implication

Diagnostic evaluation reveals high concordance across commercial and laboratory-developed tests in suspected COVID-19 cases, highlighting the utility of maintaining multiplatform workflows.

Key Points

To evaluate and compare the diagnostic performance of two commercial platforms (cobas SARS-CoV-2 and Amplidiag COVID-19) and a laboratory-developed test for detecting SARS-CoV-2 RNA in respiratory samples.
Tested 183 respiratory specimens from individuals with suspected COVID-19 across all three diagnostic platforms.
Defined the consensus reference standard as concordance between at least two of the three evaluated methods and conducted dilution series of positive samples to assess analytical sensitivity.
The cobas assay demonstrated a positive percent agreement (PPA) of 100% and a negative percent agreement (NPA) of 89.4% relative to the reference standard.
The Amplidiag assay and the laboratory-developed test each exhibited a PPA of 98.9%, with NPA values of 98.8% and 100%, respectively.
Specimen dilution series revealed markedly higher analytical sensitivity for the cobas platform compared with the Amplidiag assay and the laboratory-developed test.

Cite This Study

Mannonen et al. (2021) studied this question.

synapsesocial.com/papers/6a9475b46d20e72ae3707eed https://doi.org/10.1016/j.jmoldx.2021.01.005

View Full Paper

Ask AI

Bookmark

Implication

Diagnostic evaluation reveals high concordance across commercial and laboratory-developed tests in suspected COVID-19 cases, highlighting the utility of maintaining multiplatform workflows.

Comparison of Two Commercial Platforms and a Laboratory-Developed Test for Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA

Discussion

Member takes

Implication

Key Points

Cite This Study

Comparison of Two Commercial Platforms and a Laboratory-Developed Test for Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider